[HTML][HTML] Clinical characteristics and treatment experience of individuals with SCN8A developmental and epileptic encephalopathy (SCN8A-DEE): Findings from an …
…, MF Hammer, J Schreiber, C Grayson, C Luzon… - Seizure, 2022 - Elsevier
Purpose SCN8A developmental epileptic encephalopathy (SCN8A-DEE) is a rare and severe
genetic epilepsy syndrome characterized by early-onset developmental delay, cognitive …
genetic epilepsy syndrome characterized by early-onset developmental delay, cognitive …
Pharmacokinetics of XEN496, a novel pediatric formulation of ezogabine, under fed and fasted conditions: a phase 1 trial
R Namdari, C Luzon, JA Cadieux, J Leung… - Neurology and …, 2022 - Springer
Introduction XEN496 is a novel, granular, immediate-release formulation of ezogabine
intended for pediatric use. The objective of this study was to assess the effect of food on the …
intended for pediatric use. The objective of this study was to assess the effect of food on the …
[PDF][PDF] Phase 2b Efficacy and safety of XEN1101, a novel potassium channel modulator, in adults with focal epilepsy (X-TOLE)
…, E Aycardi, C Harden, Y Xu, C Luzon… - Chicago, IL, USA …, 2021 - xenon-pharma.com
… Rogawski,5 Simon Pimstone,6 Ernesto Aycardi,6 Cynthia Harden,6 Yi Xu,6 Constanza
Luzon,6 Christopher Kenney,6 Gregory N Beatch6 …
Luzon,6 Christopher Kenney,6 Gregory N Beatch6 …
[PDF][PDF] Phase 2b Efficacy and Safety of XEN1101, a Novel Potassium Channel Opener, in Adults With Focal Onset Seizures (X-TOLE)
…, S Pimstone, E Aycardi, C Harden, Y Xu, C Luzon… - …, 2022 - xenon-pharma.com
CONCLUSIONS ▪ XEN1101 showed a dose-dependent and highly statistically significant
reduction in FOS across endpoints in a patient population who had failed a median of 6 ASMs …
reduction in FOS across endpoints in a patient population who had failed a median of 6 ASMs …
Phase 2b efficacy and safety of XEN1101, a novel potassium channel opener, in adults with focal epilepsy (X-TOLE)(P12-8.006)
…, S Pimstone, E Aycardi, C Harden, Y Xu, C Luzon… - 2022 - AAN Enterprises
… Constanza Luzon has received personal compensation for serving as an employee of Xenon
Pharmaceuticals Inc.. Constanza Luzon has received stock or an ownership interest from …
Pharmaceuticals Inc.. Constanza Luzon has received stock or an ownership interest from …
XEN1101, a Novel Potassium Channel Modulator: Interim Data From an Ongoing, Long-Term, Open-Label Extension of a Phase 2b study (X-TOLE) in Adults with …
…, M Rogawski, C Harden, J Qian, C Luzon-Rosenblut… - 2023 - AAN Enterprises
… Constanza Luzon has received personal compensation for serving as an employee of Xenon
Pharmaceuticals Inc.. Constanza Luzon has stock in Xenon Pharmaceuticals. Christopher …
Pharmaceuticals Inc.. Constanza Luzon has stock in Xenon Pharmaceuticals. Christopher …
An Online Survey of Caregivers of Patients with KCNQ2 Developmental & Epileptic Encephalopathy (KCNQ2-DEE)(4775)
C Harden, N Butterfield, C Grayson, C Luzon… - 2020 - AAN Enterprises
Objective: We conducted an online survey to understand the clinical presentation of KCNQ2
developmental and epileptic encephalopathy (KCNQ2-DEE). Background: KCNQ2-DEE is …
developmental and epileptic encephalopathy (KCNQ2-DEE). Background: KCNQ2-DEE is …
Reliable Count of Seizures using Diaries versus Video Electroencephalography for Seizures of KCNQ2-DEE (4934)
C Harden, C Grayson, C Luzon, N Butterfield, E Aycardi… - 2020 - AAN Enterprises
Objective: We sought evidence as to whether seizures in infants and young children with
KCNQ2 Development Epileptic Encephalopathy (KCNQ2-DEE) could be reliably counted using …
KCNQ2 Development Epileptic Encephalopathy (KCNQ2-DEE) could be reliably counted using …
Relationship Between Genetic Variants and Disease Characteristics in Patients with SCN8A Developmental and Epileptic Encephalopathy (SCN8A-DEE) or SCN8A …
D Haubenberger, C Grayson, A Cutts, C Luzon… - 2021 - AAN Enterprises
… Constanza Luzon has received personal compensation for serving as an employee of Xenon
Pharmaceuticals Inc.. Constanza Luzon has received stock or an ownership interest from …
Pharmaceuticals Inc.. Constanza Luzon has received stock or an ownership interest from …
An Online Survey of Caregivers of Patients with SCN8A-related epilepsy (4940)
C Grayson, C Harden, C Luzon, S Pimstone, E Aycardi… - 2020 - AAN Enterprises
Objective: To conduct an online survey to better understand the variability in the clinical
presentation of SCN8A-related epilepsy. Background: SCN8A Developmental & Epileptic …
presentation of SCN8A-related epilepsy. Background: SCN8A Developmental & Epileptic …
